Strategies for the design of orally bioavailable antileishmanial treatments

International Journal of Pharmaceutics

Volumn 454, Issue 1, 2013, Pages 539-552

  Pham, T T H ^a,b   Loiseau, P M ^a   Barratt, G ^b  

^a UNIV PARIS SUD   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Drug combinations; Nanoparticles; Oral administration; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DAPSONE; IMIDAZOLE DERIVATIVE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; SITAMAQUINE; TRIAZOLE DERIVATIVE;

AMINOTRANSFERASE BLOOD LEVEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; LEISHMANIASIS; LIVER DYSFUNCTION; MEAN RESIDENCE TIME; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SIDE EFFECT; SKIN LEISHMANIASIS; SURFACE PROPERTY; VISCERAL LEISHMANIASIS;

EID: 84884156394     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.07.035     Document Type: Review

References (233)

1. Adler-Moore, J.P., Proffitt, R.T., 1993. Development, characterization, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3, 429-450. (Pubitemid 24007409)
2. Al-Abdely, H.M., Graybill, J.R., Loebenberg, D., Melby, P.C., 1999. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother. 43, 2910-2914.
3. Albasarah, Y.Y., Somavarapu, S., Stapleton, P., Taylor, K.M., 2010. Chitosancoated antifungal formulations for nebulisation. J. Pharm. Pharmacol. 62, 821-828.
4. Almeida, A.J., Souto, E., 2007. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59, 478-490. (Pubitemid 47260710)
5. Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Canavate, C., Dedet, J.P., Gradoni, L., Ter Horst, R., Lopez-Velez, R., Moreno, J., 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 21, 334-359, table of contents. (Pubitemid 351555511)
6. Alvar, J., Croft, S., Olliaro, P., David, H.M., 2006. Chemotherapy in the Treatment and Control of Leishmaniasis, Advances in Parasitology. Academic Press, London, pp. 223-274.
7. Alving, C.R., 1983. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol. Ther. 22, 407-424. (Pubitemid 14201457)
8. Amarji, B., Ajazuddin Raghuwanshi, D., Vyas, S.P., Kanaujia, P., 2007. Lipid nano spheres (LNSs) for enhanced oral bioavailability of amphotericin B: development and characterization. J. Biomed. Nanotechnol. 3, 264-269. (Pubitemid 351877152)
9. Amidon, G., Lennernäs, H., Shah, V., Crison, J., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420.
10. Andrès, E., Tiphine, M., Letscher-Bru, V., Herbrecht, R., 2001. Nouvelles formes lipidiques de l'Amphotericine B. Revue de la littérature. La Revue de Médecine Interne 22, 141-150. (Pubitemid 32154333)
11. Anton, N., Saulnier, P., Gaillard, C., Porcher, E., Vrignaud, S., Benoit, J.P., 2009. Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules. Langmuir 25, 11413-11419.
12. Antoniadou, A., Dupont, B., 2005. Lipid formulations of amphotericin B: where are we today? J. Med. Mycol. 15, 230-238. (Pubitemid 41774269)
13. Artursson, P., Lindmark, T., Davis, S.S., Illum, L., 1994. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11, 1358-1361. (Pubitemid 24287420)
14. Ashford, R.W., 1997. The leishmaniases as model zoonoses. Ann. Trop. Med. Parasitol. 91, 693-701. (Pubitemid 27480434)
15. Ashutosh Sundar, S., Goyal, N., 2007. Molecular mechanisms of antimony resistance in leishmania. J. Med. Microbiol. 56, 143-153.
16. Asthana, S., Jaiswal, A.K., Gupta, P.K., Pawar, V.K., Dube, A., Chourasia, M.K., 2013. Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B encapsulated nano-emulsion template based chitosan nanocapsules. Antimicrob. Agents Chemother. 57, 1714-1722.
17. Balaña-Fouce, R., Reguera, R.M., Cubría, J.C., Ordóñez, D., 1998. The pharmacology of leishmaniasis. Gen. Pharmacol. Vasc. Syst. 30, 435-443. (Pubitemid 28102818)
18. Balasegaram, M., Ritmeijer, K., Lima, M.A., Burza, S., Ortiz Genovese, G., Milani, B., Gaspani, S., Potet, J., Chappuis, F., 2012. Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin. Emerg. Drugs 17, 493-510.
19. Banerjee, G., Nandi, G., Mahato, S.B., Pakrashi, A., Basu, M.K., 1996. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J. Antimicrob. Chemother. 38, 145-150. (Pubitemid 126449219)
20. Barratt, G., Bretagne, S., 2007. Optimizing efficacy of amphotericin B through nanomodification. Int. J. Nanomed. 2, 301-313. (Pubitemid 350047775)
21. Basselin, M., Denise, H., Coombs, G.H., Barrett, M.P., 2002. Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob. Agents Chemother. 46, 3731-3738. (Pubitemid 35403244)
22. Basu, M.K., Lala, S., 2004. Macrophage specific drug delivery in experimental leishmaniasis. Curr. Mol. Med. 4, 681-689. (Pubitemid 39172370)
23. Bekers, O., Uijtendaal, E.V., Beijnen, J.H., Bult, A., Underberg, W.J.M., 1991. Cyclodextrins in the pharmaceutical field. Drug Dev. Ind. Pharm. 17, 1503-1549.
24. Berman, J., Ksionski, D., Chapman, G.W., Waits, L.V., Hanson, B.W.L., 1992. Activity of Amphotericin B Cholesterol Dispersion (Amphocil) in Experimental Visceral Leishmaniasis. American Society for Microbiology, Washington, DC, ETATSUNIS.
25. Berman, J., 2005. Recent developments in leishmaniasis: epidemiology, diagnosis, and treatment. Curr. Infect. Dis. Rep. 7, 33-38. (Pubitemid 40220526)
26. Berman, J.D., 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10, 560-586.
27. Berman, J.D., 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24, 684-703. (Pubitemid 27143564)
28. Berman, J.D., Badaro, R., Thakur, C.P., Wasunna, K.M., Behbehani, K., Davidson, R., Kuzoe, F., Pang, L., Weerasuriya, K., Bryceson, A.D., 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. 76, 25-32. (Pubitemid 28254976)
29. Berman, J.D., Hanson, W.L., Chapman, W.L., Alving, C.R., Lopez-Berestein, G., 1986. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob. Agents Chemother. 30, 847-851.
30. Bern, C., Adler-Moore, J., Berenguer, J., Boelaert, M., den Boer, M., Davidson, R.N., Figueras, C., Gradoni, L., Kafetzis, D.A., Ritmeijer, K., Rosenthal, E., Royce, C., Russo, R., Sundar, S., Alvar, J., 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis. 43, 917-924. (Pubitemid 44435523)
31. Bernkop-Schnürch, A., 2013. Nanocarrier systems for oral drug delivery: do we really need them? Eur. J. Pharm. Sci. 49, 272-277.
32. Boelaert, M., Criel, B., Leeuwenburg, J., Van Damme, W., Le Ray, D., Van der Stuyft, P., 2000. Visceral leishmaniasis control: a public health perspective. Trans. R. Soc. Trop. Med. Hyg. 94, 465-471.
33. Bolard, J., 1986. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta 864, 257-304. (Pubitemid 17228111)
34. Bora, D., 1999. Epidemiology of visceral leishmaniasis in India. Natl. Med. J. India 12, 62-68.
35. Bories, C., Cojean, S., Huteau, F., Loiseau, P.M., 2008. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani. Biomed. Pharmacother. 62, 164-167. (Pubitemid 351381937)
36. Boyd, B.J., Whittaker, D.V., Khoo, S.M., Davey, G., 2006. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int. J. Pharm. 309, 218-226. (Pubitemid 43129485)
37. Brajtburg, J., Powderly, W.G., Kobayashi, G.S., Medoff, G., 1990. Amphotericin B: delivery systems. Antimicrob. Agents Chemother. 34, 381-384. (Pubitemid 20068656)
38. Bray, P.G., Barrett, M.P., Ward, S.A., de Koning, H.P., 2003. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol. 19, 232-239. (Pubitemid 36588598)
39. Bryceson, A., 2001a. Current issues in the treatment of visceral leishmaniasis. Med. Microbiol. Immunol. 190, 81-84. (Pubitemid 33079365)
40. Bryceson, A., 2001b. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 6, 928-934. (Pubitemid 33010880)
41. Carvalho, L., Luque-Ortega, J.R., Lopez-Martin, C., Castanys, S., Rivas, L., Gamarro, F., 2011. The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase. Antimicrob. Agents Chemother. 55, 4204-4210.
42. Chan-Bacab, M.J., Pena-Rodriguez, L.M., 2001. Plant natural products with leishmanicidal activity. Nat. Prod. Rep. 18, 674-688. (Pubitemid 34010018)
43. Chapman Jr., W.L., Hanson, W.L., Alving, C.R., Hendricks, L.D., 1984. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am. J. Vet. Res. 45, 1028-1030. (Pubitemid 14113845)
44. Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R.W., Alvar, J., Boelaert, M., 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5, 873-882. (Pubitemid 47578388)
45. Chung, H., Kim, J., Um, J.Y., Kwon, I.C., Jeong, S.Y., 2002. Self-assembled nanocubicle as a carrier for peroral insulin delivery. Diabetologia 45, 448-451. (Pubitemid 34267369)
46. Cojean, S., Houze, S., Haouchine, D., Huteau, F., Lariven, S., Hubert, V., Michard, F., Bories, C., Pratlong, F., Le Bras, J., Loiseau, P.M., Matheron, S., 2012. Leishmania resistance to miltefosine associated with genetic marker. Emerg. Infect. Dis. 18, 704-706.
47. Couvreur, P., Puisieux, F., 1993. Nano- and microparticles for the delivery of polypeptides and proteins. Adv. Drug Deliv. Rev. 10, 141-162. (Pubitemid 23172580)
48. Couvreur, P., Tulkens, P., Roland, M., Trouet, A., Speiser, P., 1977. Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett. 84, 323-326. (Pubitemid 8246984)
49. Croft, S.L., Coombs, G.H., 2003. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19, 502-508. (Pubitemid 37329659)
50. Croft, S.L., Neal, R.A., Pendergast, W., Chan, J.H., 1987. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 36, 2633-2636. (Pubitemid 17102920)
51. Croft, S.L., Sundar, S., Fairlamb, A.H., 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19, 111-126. (Pubitemid 43157649)
52. Dangi, J.S., Vyas, S.P., Dixit, V.K., 1998. Effect of various lipid-bile salt mixed micelles on the intestinal absorption of amphotericin-B in rat. Drug Dev. Ind. Pharm. 24, 631-635. (Pubitemid 28312300)
53. Davidson, R.N., 1998. Practical guide for the treatment of leishmaniasis. Drugs 56, 1009-1018. (Pubitemid 29010219)
54. Davidson, R.N., Scott, A., Maini, M., Bryceson, A.D.M., Croft, S.L., 1991. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337, 1061-1062.
55. Delmas, G., Park, S., Chen, Z.W., Tan, F., Kashiwazaki, R., Zarif, L., Perlin, D.S., 2002. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob. Agents Chemother. 46, 2704-2707. (Pubitemid 34793493)
56. Demicheli, C., Ochoa, R., da Silva, J.B., Falcao, C.A., Rossi-Bergmann, B., de Melo, A.L., Sinisterra, R.D., Frezard, F., 2004. Oral delivery of meglumine antimoniatebeta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob. Agents Chemother. 48, 100-103. (Pubitemid 38040183)
57. Denerolle, P., Bourdoiseau, G., 1999. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). J. Vet. Intern. Med. 13, 413-415.
58. Desjeux, P., 1996. Leishmaniasis: public health aspects and control. Clin. Dermatol. 14, 417-423. (Pubitemid 26327735)
59. Douglas, J.B., Healy, J.K., 1969. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am. J. Med. 46, 154-162.
60. Du, Y.Z., Wang, L., Yuan, H., Wei, X.H., Hu, F.Q., 2009. Preparation and characteristics of linoleic acid-grafted chitosan oligosaccharide micelles as a carrier for doxorubicin. Colloids Surf. B: Biointerfaces 69, 257-263.
61. Dueñas-Romero, A.M., Loiseau, P.M., Saint-Pierre-Chazalet, M., 2007. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochim. Biophys. Acta (BBA): Biomembr. 1768, 246-252. (Pubitemid 46138097)
62. Duhem, N., Rolland, J., Riva, R., Guillet, P., Schumers, J.-M., Jérome, C., Gohy, J.-F., Préat, V., 2012. Tocol modified glycol chitosan for the oral delivery of poorly soluble drugs. Int. J. Pharm. 423, 452-460.
63. Espuelas, M.S., Legrand, P., Loiseau, P.M., Bories, C., Barratt, G., Irache, J.M., 2002. In vitro antileishmanial activity of amphotericin B loaded in poly(epsiloncaprolactone) nanospheres. J. Drug Target. 10, 593-599.
64. Fournet, A., Munoz, V., 2002. Natural products as trypanocidal, antileishmanial and antimalarial drugs. Curr. Top. Med. Chem. 2, 1215-1237.
65. Frézard, F., Demicheli, C., Ribeiro, R., 2009. Pentavalent antimonials: new perspectives for old drugs. Molecules 14, 2317-2336.
66. Frezard, F., Martins, P.S., Bahia, A.P., Le Moyec, L., de Melo, A.L., Pimenta, A.M., Salerno, M., da Silva, J.B., Demicheli, C., 2008. Enhanced oral delivery of antimony from meglumine antimoniate/beta-cyclodextrin nanoassemblies. Int. J. Pharm. 347, 102-108. (Pubitemid 350186086)
67. Gaspar, R., Opperdoes, F.R., Preat, V., Roland, M., 1992. Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann. Trop. Med. Parasitol. 86, 41-49.
68. Gershkovich, P., Sivak, O., Wasan, E.K., Magil, A.B., Owen, D., Clement, J.G., Wasan, K.M., 2010. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). J. Antimicrob. Chemother. 65, 2610-2613.
69. Gershkovich, P., Wasan, E.K., Lin, M., Sivak, O., Leon, C.G., Clement, J.G., Wasan, K.M., 2009. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J. Antimicrob. Chemother. 64, 101-108.
70. Gilani, K., Moazeni, E., Ramezanli, T., Amini, M., Fazeli, M.R., Jamalifar, H., 2011. Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulization. J. Pharm. Sci. 100, 252-259.
71. Ginel, P.J., Lucena, R., Lopez, R., Molleda, J.M., 1998. Use of allopurinol for maintenance of remission in dogs with leishmaniasis. J. Small Anim. Pract. 39, 271-274. (Pubitemid 128527594)
72. Giri, T.K., Thakur, A., Alexander, A., Ajazuddin Badwaik, H., Tripathi, D.K., 2012. Modified chitosan hydrogels as drug delivery and tissue engineering systems: present status and applications. Acta Pharm. Sin. B 2, 439-449.
73. Gruda, I., Dussault, N., 1988. Effect of the aggregation state of amphotericin B on its interaction with ergosterol. Biochem. Cell Biol. 66, 177-183.
74. Guerin, P.J., Olliaro, P., Sundar, S., Boelaert, M., Croft, S.L., Desjeux, P., Wasunna, M.K., Bryceson, A.D.M., 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2, 494-501. (Pubitemid 34826855)
75. Gupta, S., Pal, A., Vyas, S.P., 2010. Drug delivery strategies for therapy of visceral leishmaniasis. Expert Opin. Drug Deliv. 7, 371-402.
76. Halde, C., Newcomer, V.D., Wright, E.T., Sternberg, T.H., 1957. An evaluation of amphotericin B in vitro and in vivo in mice against Coccidioides immitis and Candida albicans, and preliminary observations concerning the administration of amphotericin B to man. J. Invest. Dermatol. 28, 217-231 (discussion 231-212).
77. Hartsel, S., Bolard, J., 1996. Amphotericin B: new life for an old drug. Trends Pharmacol. Sci. 17, 445-449. (Pubitemid 27028476)
78. Hauss, D.J., Fogal, S.E., Ficorilli, J.V., Price, C.A., Roy, T., Jayaraj, A.A., Keirns, J.J., 1998. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 87, 164-169.
79. Heath, S., Chance, M.L., New, R.R.C., 1984. Quantitative and ultrastructural studies on the uptake of drug loaded liposomes by mononuclear phagocytes infected with Leishmania donovani. Mol. Biochem. Parasitol. 12, 49-60. (Pubitemid 14056236)
80. Herwaldt, B.L., 1999. Leishmaniasis. Lancet 354, 1191-1199. (Pubitemid 29460458)
81. Herwaldt, B.L., Berman, J.D., 1992. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 46, 296-306.
82. Heurtault, B., Saulnier, P., Pech, B., Proust, J.E., Benoit, J.P., 2002. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 19, 875-880. (Pubitemid 34692585)
83. Huynh, N.T., Passirani, C., Saulnier, P., Benoit, J.P., 2009. Lipid nanocapsules: a new platform for nanomedicine. Int. J. Pharm. 379, 201-209.
84. Ibrahim, F., Gershkovich, P., Sivak, O., Wasan, E.K., Bartlett, K., Wasan, K.M., 2012a. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. Int. J. Pharm. 436, 318-323.
85. Ibrahim, F., Gershkovich, P., Sivak, O., Wasan, E.K., Wasan, K.M., 2012b. Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model. Eur. J. Pharm. Sci. 46, 323-328.
86. Illum, L., 1998. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15, 1326-1331. (Pubitemid 28427917)
87. Italia, J.L., Kumar, M.N., Carter, K.C., 2012. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis. J. Biomed. Nanotechnol. 8, 695-702.
88. Italia, J.L., Sharp, A., Carter, K.C., Warn, P., Kumar, M.N.V.R., 2011. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™. PLoS ONE 6, e25744.
89. Italia, J.L., Yahya, M.M., Singh, D., Ravi Kumar, M.N., 2009. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous fungizone. Pharm. Res. 26, 1324-1331.
90. Jain, S., Valvi, P.U., Swarnakar, N.K., Thanki, K., 2012. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B. Mol. Pharm. 9, 2542-2553.
91. Janoff, A.S., Boni, L.T., Popescu, M.C., Minchey, S.R., Cullis, P.R., Madden, T.D., Taraschi, T., Gruner, S.M., Shyamsunder, E., Tate, M.W., et al., 1988. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. U.S.A. 85, 6122-6126.
92. Jha, T.K., Sundar, S., Thakur, C.P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., Berman, J., 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341, 1795-1800.
93. Jha, T.K., Sundar, S., Thakur, C.P., Felton, J.M., Sabin, A.J., Horton, J., 2005. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg. 73, 1005-1011. (Pubitemid 43038244)
94. Jhingran, A., Chawla, B., Saxena, S., Barrett, M.P., Madhubala, R., 2009. Paromomycin: uptake and resistance in Leishmania donovani. Mol. Biochem. Parasitol. 164, 111-117.
95. Jin, T., Zarif, L., Mannino, R.J., 2000. Nano-cochleate formulations, process of preparation and method of delivery of pharmaceutical agents, U.S.A.
96. Joly, V., Saint-Pierre-Chazalet, M., Saint-Julien, L., Bolard, J., Carbon, C., Yeni, P., 1992. Inhibiting cholesterol synthesis reduces the binding and toxicity of amphotericin B against rabbit renal tubular cells in primary culture. J. Infect. Dis. 165, 337-343.
97. Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., 2011. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int. J. Pharm. 420, 1-10.
98. Kayser, O., 2000. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages. Int. J. Pharm. 196, 253-256. (Pubitemid 30105755)
99. Kayser, O., Olbrich, C., Yardley, V., Kiderlen, A.F., Croft, S.L., 2003. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254, 73-75. (Pubitemid 36259814)
100. Kedzierski, L., Zhu, Y., Handman, E., 2006. Leishmania vaccines: progress and problems. Parasitology 133 (Suppl.), S87-S112. (Pubitemid 46208033)
101. Kesisoglou, F., Panmai, S., Wu, Y., 2007. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59, 631-644. (Pubitemid 47285408)
102. Kockisch, S., Rees, G.D., Young, S.A., Tsibouklis, J., Smart, J.D., 2003. Polymeric microspheres for drug delivery to the oral cavity: an in vitro evaluation of mucoadhesive potential. J. Pharm. Sci. 92, 1614-1623. (Pubitemid 36929681)
103. Kotta, S., Khan, A.W., Pramod, K., Ansari, S.H., Sharma, R.K., Ali, J., 2012. Exploring oral nanoemulsions for bioavailability enhancement of poorly water-soluble drugs. Expert Opin. Drug Deliv. 9, 585-598.
104. Koutinas, A.F., Saridomichelakis, M.N., Mylonakis, M.E., Leontides, L., Polizopoulou, Z., Billinis, C., Argyriadis, D., Diakou, N., Papadopoulos, O., 2001. A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vet. Parasitol. 98, 247-261. (Pubitemid 32553825)
105. Kreuter, J., 1991. Liposomes and nanoparticles as vehicles for antibiotics. Infection 19, S224-S228.
106. Kuhlencord, A., Maniera, T., Eibl, H., Unger, C., 1992. Hexadecylphosphocholine: Oral Treatment of Visceral Leishmaniasis in Mice. American Society for Microbiology, Washington, DC, ETATS-UNIS.
107. Kumar, M.N., Muzzarelli, R.A., Muzzarelli, C., Sashiwa, H., Domb, A.J., 2004. Chitosan chemistry and pharmaceutical perspectives. Chem. Rev. 104, 6017-6084. (Pubitemid 40025733)
108. Kurkov, S.V., Loftsson, T., 2012. Cyclodextrins. Int. J. Pharm., http://dx.doi.org/10.1016/j.ijpharm.2012.06.055.
109. Lala, S., Pramanick, S., Mukhopadhyay, S., Bandyopadhyay, S., Basu, M.K., 2004. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J. Drug Target. 12, 165-175.
110. Lambert, G., Fattal, E., Pinto-Alphandary, H., Gulik, A., Couvreur, P., 2000. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 17, 707-714. (Pubitemid 30670637)
111. Langer, R., Folkman, J., 1976. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797-800.
112. Laza-Knoerr, A.L., Gref, R., Couvreur, P., 2010. Cyclodextrins for drug delivery. J. Drug Target. 18, 645-656.
113. Lemke, A., Kiderlen, A.F., Kayser, O., 2005. Amphotericin B. Appl. Microbiol. Biotechnol. 68, 151-162. (Pubitemid 41110936)
114. Leon, C.G., Lee, J., Bartlett, K., Gershkovich, P., Wasan, E.K., Zhao, J., Clement, J.G., Wasan, K.M., 2011. In vitro cytotoxicity of two novel oral formulations of amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines. Lipids Health Dis. 10, 144.
115. Lira, R., Sundar, S., Makharia, A., Kenney, R., Gam, A., Saraiva, E., Sacks, D., 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180, 564-567.
116. Littman, M.L., Horowitz, P.L., Swadey, J.G., 1958. Coccidioidomycosis and its treatment with amphotericin B. Am. J. Med. 24, 568-592.
117. Loftsson, T., Jarho, P., Masson, M., Jarvinen, T., 2005. Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. 2, 335-351. (Pubitemid 41130887)
118. Lopes, R., Eleutério, C.V., Gonçalves, L.M.D., Cruz, M.E.M., Almeida, A.J., 2012. Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis. Eur. J. Pharm. Sci. 45, 442-450.
119. Louria, D.B., 1958. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antib. Med. Clin. Ther. 5, 295-301.
120. Lu, Y., Park, K., 2012. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm., http://dx.doi.org/ 10.1016/j.ijpharm.2012.08.042.
121. Lynch, M.L., Ofori-Boateng, A., Hippe, A., Kochvar, K., Spicer, P.T., 2003. Enhanced loading of water-soluble actives into bicontinuous cubic phase liquid crystals using cationic surfactants. J. Colloids Interface Sci. 260, 404-413. (Pubitemid 36401600)
122. Mannino, R.J., Canki, M., Feketeova, E., Scolpino, A.J., Wang, Z., Zhang, F., Kheiri, M.T., Gould-Fogerite, S., 1998. Targeting immune response induction with cochleate and liposome-based vaccines. Adv. Drug Deliv. Rev. 32, 273-287. (Pubitemid 28267413)
123. Marr, J.J., 1991. Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J. Lab. Clin. Med. 118, 111-119.
124. Martins, P.S., Ochoa, R., Pimenta, A.M.C., Ferreira, L.A.M., Melo, A.L., da Silva, J.B.B., Sinisterra, R.D., Demicheli, C., Frézard, F., 2006. Mode of action of β-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. Int. J. Pharm. 325, 39-47. (Pubitemid 44608216)
125. McGwire, B.S., Satoskar, A.R., 2013. Leishmaniasis: clinical syndromes and treatment. QJM, http://dx.doi.org/10.1093/qjmed/hct116.
126. Mehnert, W., Mäder, K., 2001. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47, 165-196. (Pubitemid 32324113)
127. Melaku, Y., Collin, S.M., Keus, K., Gatluak, F., Ritmeijer, K., Davidson, R.N., 2007. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am. J. Trop. Med. Hyg. 77, 89-94.
128. Ménez, C., Buyse, M., Besnard, M., Farinotti, R., Loiseau, P.M., Barratt, G., 2006a. Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Antimicrob. Agents Chemother. 50, 3793-3800. (Pubitemid 44684895)
129. Ménez, C., Buyse, M., Chacun, H., Farinotti, R., Barratt, G., 2006b. Modulation of intestinal barrier properties by miltefosine. Biochem. Pharmacol. 71, 486-496. (Pubitemid 43077083)
130. Ménez, C., Legrand, P., Rosilio, V., Lesieur, S., Barratt, G., 2007. Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B. Mol. Pharm. 4, 281-288. (Pubitemid 46640604)
131. Meunier, F., Prentice, H.G., Ringdén, O., 1991. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28, 83-91.
132. Minkov, I., Ivanova, T., Panaiotov, I., Proust, J., Saulnier, P., 2005. Reorganization of lipid nanocapsules at air-water interface: part 2. Properties of the formed surface film. Colloids Surf. B: Biointerfaces 44, 197-203. (Pubitemid 44302094)
133. Monzote, L., 2009. Current treatment of leishmaniasis: a review. Open Antimicrob. Agents J. 1, 9-19.
134. Mu, H., Holm, R., Müllertz, A., 2013. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int. J. Pharm., http://dx.doi.org/10.1016/j.ijpharm.2013.03.054.
135. Mukhopadhyay, P., Mishra, R., Rana, D., Kundu, P.P., 2012. Strategies for effective oral insulin delivery with modified chitosan nanoparticles: a review. Progr. Polym. Sci. 37, 1457-1475.
136. Mullen, A.B., Baillie, A.J., Carter, K.C., 1998. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob. Agents Chemother. 42, 2722-2725. (Pubitemid 28462922)
137. Müller, R.H., 2007. Lipid nanoparticles: recent advances. Adv. Drug Deliv. Rev. 59, 375-376. (Pubitemid 47260708)
138. Muller, R.H., Jacobs, C., Kayser, O., 2001. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3-19. (Pubitemid 32209229)
139. Muller, R.H., Mader, K., Gohla, S., 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161-177. (Pubitemid 30326695)
140. Müller, R.H., Peters, K., 1998. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int. J. Pharm. 160, 229-237. (Pubitemid 28083096)
141. Murray, H.W., Berman, J.D., Davies, C.R., Saravia, N.G., 2005. Advances in leishmaniasis. Lancet 366, 1561-1577. (Pubitemid 41540115)
142. Newman, D.J., 2008. Natural products as leads to potential drugs: an old process or the new hope for drug discovery. J. Med. Chem. 51, 2589-2599. (Pubitemid 351620778)
143. Nieto, J., Alvar, J., Mullen, A.B., Carter, K.C., Rodriguez, C., San Andres, M.I., San Andres, M.D., Baillie, A.J., Gonzalez, F., 2003. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob. Agents Chemother. 47, 2781-2787. (Pubitemid 37040248)
144. Nyakundi, P.M., Wasunna, K.M., Rashid, J.R., Gachihi, G.S., Mbugua, J., Kirigi, G., Muttunga, J., 1994. Is one year follow-up justified in kala-azar post-treatment? East Afr. Med. J. 71, 453-459.
145. Olliaro, P.L., Bryceson, A.D., 1993. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol. Today 9, 323-328. (Pubitemid 23238274)
146. Papahadjopoulos, D., Portis, A., Pangborn, W., 1978a. Calcium-induced lipid phase transition and membrane fusion. Ann. N. Y. Acad. Sci. 308, 50-66. (Pubitemid 8372517)
147. Papahadjopoulos, D., Portis, A., Pangborn, W., 1978b. Calcium induced phase changes and fusion in natural in natural and model membranes. Ann. N. Y. Acad. Sci. 308, 50-66. (Pubitemid 8372517)
148. Papahadjopoulos, D., Vail, W.J., Jacobson, K., Poste, G., 1975. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta (BBA): Biomembr. 394, 483-491.
149. Paris, C., Loiseau, P.M., Bories, C., Breard, J., 2004. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 48, 852-859. (Pubitemid 38280335)
150. Patel, P.A., Patravale, V.B., 2011. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J. Biomed. Nanotechnol. 7, 632-639.
151. Pathak, M.K., Yi, T., 2001. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 167, 3391-3397. (Pubitemid 32852583)
152. Paul, M., Durand, R., Boulard, Y., Fusai, T., Fernandez, C., Rivollet, D., Deniau, M., Astier, A., 1998. Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J. Drug Target. 5, 481-490. (Pubitemid 28499682)
153. Payne, G.F., Chaubal, M.V., Barbari, T.A., 1996. Enzyme-catalysed polymer modification: reaction of phenolic compounds with chitosan films. Polymer 37, 4643-4648. (Pubitemid 126382285)
154. Peng, X., Wen, X., Pan, X., Wang, R., Chen, B., Wu, C., 2010. Design and in vitro evaluation of capsaicin transdermal controlled release cubic phase gels. AAPS PharmSciTech 11, 1405-1410.
155. Pérez-Victoria, F.J., Sánchez-Canete, M.a.P., Seifert, K., Croft, S.L., Sundar, S., Castanys, S., Gamarro, F., 2006. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist. Updat. 9, 26-39. (Pubitemid 43928805)
156. Perez-Victoria, F.J., Sanchez-Canete, M.P., Seifert, K., Croft, S.L., Sundar, S., Castanys, S., Gamarro, F., 2006. Mechanisms of experimental resistance of leishmania to miltefosine: implications for clinical use. Drug Resist. Updat. 9, 26-39. (Pubitemid 43928805)
157. Polonio, T., Efferth, T., 2008. Leishmaniasis: drug resistance and natural products (review). Int. J. Mol. Med. 22, 277-286.
158. Porter, C.J., Trevaskis, N.L., Charman, W.N., 2007. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6, 231-248. (Pubitemid 46344627)
159. Porter, C.J.H., Charman, W.N., 2001. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 50, 61-80. (Pubitemid 32727277)
160. Pouton, C.W., 2006. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 29, 278-287. (Pubitemid 44740131)
161. Prasad, R., Kumar, R., Jaiswal, B., Singh, U., 2004. Miltefosine: an oral drug for visceral leishmaniasis. Indian J. Pediatr. 71, 143-144. (Pubitemid 38325649)
162. Purkait, B., Kumar, A., Nandi, N., Sardar, A.H., Das, S., Kumar, S., Pandey, K., Ravidas, V., Kumar, M., De, T., Singh, D., Das, P., 2012. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 56, 1031-1041.
163. Rahman, M.A., Harwansh, R., Mirza, M.A., Hussain, S., Hussain, A., 2011. Oral lipid based drug delivery system (LBDDS): formulation, characterization and application: a review. Curr. Drug Deliv. 8, 330-345.
164. Ren, Y., Wang, G., Huang, J., 2007. Preparation of liquid-core nanocapsules from poly[(ethylene oxide)-co-glycidol] with multiple hydrophobic linoleates at an oil-water interface and its encapsulation of pyrene. Biomacromolecules 8, 1873-1880. (Pubitemid 47009966)
165. Requena, J.M., Iborra, S., Carrion, J., Alonso, C., Soto, M., 2004. Recent advances in vaccines for leishmaniasis. Expert Opin. Biol. Ther. 4, 1505-1517. (Pubitemid 39222982)
166. Ribeiro, R.R., Ferreira, W.A., Martins, P.S., Neto, R.L., Rocha, O.G., Le Moyec, L., Demicheli, C., Frezard, F., 2010. Prolonged absorption of antimony(V) by the oral route from non-inclusion meglumine antimoniate-beta- cyclodextrin conjugates. Biopharm. Drug Dispos. 31, 109-119.
167. Risovic, V., Boyd, M., Choo, E., Wasan, K.M., 2003. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob. Agents Chemother. 47, 3339-3342. (Pubitemid 37229601)
168. Robbie, G., Wu, T.-C., Chiou, W., 1999. Poor and unusually prolonged oral absorption of amphotericin B in rats. Pharm. Res. 16, 455-458. (Pubitemid 29162106)
169. Roberts, L.J., Janovy, J., 2000. Foundations of Parasitology. McGraw-Hill Science/Engineering/Math, Boston.
170. Rojas-Aguirre, Y., Yepez-Mulia, L., Castillo, I., Lopez-Vallejo, F., Soria-Arteche, O., Hernandez-Campos, A., Castillo, R., Hernandez-Luis, F., 2011. Studies on 6-chloro-5-(1-naphthyloxy)-2-(trifluoromethyl)-1H-benzimidazole/2- hydroxypropyl-b eta-cyclodextrin association: characterization, molecular modeling studies, and in vivo anthelminthic activity. Bioorg. Med. Chem. 19, 789-797.
171. Saint-Pierre-Chazalet, M., Thomas, C., Dupeyrat, M., Gary-Bobo, C.M., 1988. Amphotericin B-sterol complex formation and competition with egg phosphatidylcholine: a monolayer study. Biochimica et Biophysica Acta (BBA) - Biomembranes 944, 477-486.
172. Sankar, V., Reddy, Y., 2010. Nanocochleate - a new approach in lipid drug delivery. Int. J. Pharm. Pharm. Sci. 2, 220-223.
173. Sant, V.P., Smith, D., Leroux, J.-C., 2005. Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylateco-methacrylic acid) self-assemblies. J. Control. Release 104, 289-300. (Pubitemid 40724930)
174. Santangelo, R., Paderu, P., Delmas, G., Chen, Z.W., Mannino, R., Zarif, L., Perlin, D.S., 2000.Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob. Agents Chemother. 44, 2356-2360.
175. Santos-Magalhaes, N.S., Pontes, A., Pereira, V.M., Caetano, M.N., 2000. Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules. Int. J. Pharm. 208, 71-80.
176. Sarkar, S., Mandal, S., Sinha, J., Mukhopadhyay, S., Das, N., Basu, M.K., 2002. Quercetin: critical evaluation as an antileishmanial agent in vivo in hamsters using different vesicular delivery modes. J. Drug Target. 10, 573-578.
177. Sarmento, B., Ribeiro, A., Veiga, F., Sampaio, P., Neufeld, R., Ferreira, D., 2007. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res. 24, 2198-2206. (Pubitemid 350060707)
178. Satturwar, P., Eddine, M.N., Ravenelle, F., Leroux, J.C., 2007. pH-responsive polymeric micelles of poly(ethylene glycol)-b-poly(alkyl(meth) acrylate-co-methacrylic acid): influence of the copolymer composition on self-assembling properties and release of candesartan cilexetil. Eur. J. Pharm. Biopharm. 65, 379-387.
179. Schipper, N.G.M., Vårum, K.M., Stenberg, P., Ocklind, G., Lennernäs, H., Artursson, P., 1999. Chitosans as absorption enhancers of poorly absorbable drugs: 3: influence of mucus on absorption enhancement. Eur. J. Pharm. Sci. 8, 335-343.
180. Scott, J.A., Davidson, R.N., Moody, A.H., Grant, H.R., Felmingham, D., Scott, G.M., Olliaro, P., Bryceson, A.D., 1992. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom. Trans. R. Soc. Trop. Med. Hyg. 86, 617-619. (Pubitemid 23012904)
181. Seifert, K., Matu, S., Javier Pérez-Victoria, F., Castanys, S., Gamarro, F., Croft, S.L., 2003. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents 22, 380-387.
182. Seifert, K., Perez-Victoria, F.J., Stettler, M., Sanchez-Canete, M.P., Castanys, S., Gamarro, F., Croft, S.L., 2007. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int. J. Antimicrob. Agents 30, 229-235. (Pubitemid 47135625)
183. Sesana, A.M., Monti-Rocha, R., Vinhas, S.A., Morais, C.G., Dietze, R., Lemos, E.M., 2011. In vitro activity of amphotericin B cochleates against Leishmania chagasi. Memórias do Instituto Oswaldo Cruz 106, 251-253.
184. Shah, J.C., Sadhale, Y., Chilukuri, D.M., 2001. Cubic phase gels as drug delivery systems. Adv. Drug Deliv. Rev. 47, 229-250. (Pubitemid 32324116)
185. Silva, A.E., Barratt, G., Chéron, M., Egito, E.S.T., 2013. Development of oil-in-water microemulsions for the oral delivery of amphotericin B. Int. J. Pharm., http://dx.doi.org/10.1016/j.ijpharm.2013.05.044.
186. Singh, A., Worku, Z.A., Van den Mooter, G., 2011. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin. Drug Deliv. 8, 1361-1378.
187. Singh, R.K., Pandey, H.P., Sundar, S., 2006. Visceral leishmaniasis (kala-azar): challenges ahead. Indian J. Med. Res. 123, 331-344. (Pubitemid 43905573)
188. Singh, S., Sivakumar, R., 2004. Challenges and new discoveries in the treatment of leishmaniasis. J. Infect. Chemother. 10, 307-315. (Pubitemid 40142819)
189. Sinha, J., Mukhopadhyay, S., Das, N., Basu, M.K., 2000. Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo. Drug Deliv. 7, 209-213. (Pubitemid 32057552)
190. Sinha, J., Raay, B., Das, N., Medda, S., Garai, S., Mahato, S., Basu, M., 2002. Bacosaponin C: critical evaluation of anti-leishmanial properties in various delivery modes. Drug Deliv. 9, 55-62. (Pubitemid 34171335)
191. Sivak, O., Gershkovich, P., Lin, M., Wasan, E.K., Zhao, J., Owen, D., Clement, J.G., Wasan, K.M., 2011. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Lipids Health Dis. 10, 135-139.
192. Souza, L.C., Saldiva, P.H.r.N., Campa, A., 2000. Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study. Exp. Toxicol. Pathol. 52, 169-175. (Pubitemid 30313585)
193. Sprunk, A., Strachan, C.J., Graf, A., 2012. Rational formulation development and in vitro assessment of SMEDDS for oral delivery of poorly water soluble drugs. Eur. J. Pharm. Sci. 46, 508-515.
194. Stevens, D.A., 1994. Overview of amphotericin B colloidal dispersion (Amphocil). J. Infect. 28 (Suppl. 1), 45-49.
195. Sundar, S., 2001. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6, 849-854. (Pubitemid 33010870)
196. Sundar, S., Chatterjee, M., 2006. Visceral leishmaniasis - current therapeutic modalities. Indian J. Med. Res. 123, 345-352. (Pubitemid 43905574)
197. Sundar, S., Gupta, L.B., Rastogi, V., Agrawal, G., Murray, H.W., 2000a. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94, 200-204. (Pubitemid 30307297)
198. Sundar, S., Jha, T.K., Thakur, C.P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., Berman, J., 2002. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347, 1739-1746. (Pubitemid 35375612)
199. Sundar, S., Jha, T.K., Thakur, C.P., Sinha, P.K., Bhattacharya, S.K., 2007. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 356, 2571-2581. (Pubitemid 46961002)
200. Sundar, S., Makharia, A., More, D.K., Agrawal, G., Voss, A., Fischer, C., Bachmann, P., Murray, H.W., 2000b. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. 31, 1110-1113. (Pubitemid 32299377)
201. Sundar, S., Mehta, H., Suresh, A.V., Singh, S.P., Rai, M., Murray, H.W., 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin. Infect. Dis. 38, 377-383. (Pubitemid 38200114)
202. Sundar, S., Murray, H.W., 2005. Availability of miltefosine for the treatment of kalaazar in India. Bull. World Health Organ. 83, 394-395. (Pubitemid 40704871)
203. Sundar, S., Olliaro, P.L., 2007. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther. Clin. Risk Manage. 3, 733-740. (Pubitemid 350162073)
204. Sundar, S., Rai, M., 2005. Treatment of visceral leishmaniasis. Expert Opin. Pharmacother. 6, 2821-2829. (Pubitemid 43009545)
205. Sundar, S., Sinha, P.K., Dixon, S.A., Buckley, R., Miller, A.K., Mohamed, K., Al-Banna, M., 2011. Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India. Am. J. Trop. Med. Hyg. 84, 892-900.
206. Tadros, T., Izquierdo, P., Esquena, J., Solans, C., 2004. Formation and stability of nanoemulsions. Adv. Colloid Interf. Sci. 108-109, 303-318.
207. Tamilvanan, S., 2004. Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems. Progr. Lipid Res. 43, 489-533. (Pubitemid 39441344)
208. Tanino, T., Ogiso, T., Iwaki, M., Yamaguchi, T., Kakehi, K., 1999. Release characteristics of endogenous constituents by exposure of small intestine to modified betacyclodextrins. Biol. Pharm. Bull. 22, 1099-1105. (Pubitemid 29507951)
209. Thakur, C.P., Dedet, J.P., Narain, S., Pratlong, F., 2001. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. Trans. R. Soc. Trop. Med. Hyg. 95, 187-189. (Pubitemid 34947385)
210. Thakur, C.P., Narayan, S., Ranjan, A., 2004. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J. Med. Res. 120, 166-172. (Pubitemid 39406044)
211. Thanou, M., Verhoef, J.C., Junginger, H.E., 2001. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 50 (Suppl. 1), S91-S101. (Pubitemid 32905357)
212. Tiuman, T.S., Santos, A.O., Ueda-Nakamura, T., Filho, B.P.D., Nakamura, C.V., 2011. Recent advances in leishmaniasis treatment. Int. J. Infect. Dis. 15, e525-e532.
213. Tiyaboonchai, W., Limpeanchob, N., 2007. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int. J. Pharm. 329, 142-149. (Pubitemid 44937518)
214. Tyagi, R., Lala, S., Verma, A.K., Nandy, A.K., Mahato, S.B., Maitra, A., Basu, M.K., 2005. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J. Drug Target. 13, 161-171.
215. Veerareddy, P.R., Vobalaboina, V., Ali, N., 2009. Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheres. J. Drug Target. 17, 140-147.
216. Verkleij, A.J., de Kruyff, B., Ververgaert, P.H., Tocanne, J.F., van Deenen, L.L., 1974. The influence of pH, Ca2+ and protein on the thermotropic behaviour of the negatively charged phospholipid, phosphatidylglycerol. Biochim. Biophys. Acta 339, 432-437.
217. Verma, R.K., Pandya, S., Misra, A., 2011. Loading and release of amphotericin-B from biodegradable poly(lactic-co-glycolic acid) nanoparticles. J. Biomed. Nanotechnol. 7, 118-120.
218. Walker, J., Gongora, R., Vasquez, J.-J., Drummelsmith, J., Burchmore, R., Roy, G., Ouellette, M., Gomez, M.A., Saravia, N.G., 2012. Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol. Biochem. Parasitol. 183, 166-176.
219. Wasan, E.K., Bartlett, K., Gershkovich, P., Sivak, O., Banno, B., Wong, Z., Gagnon, J., Gates, B., Leon, C.G., Wasan, K.M., 2009. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int. J. Pharm. 372, 76-84.
220. Wasan, E.K., Gershkovich, P., Zhao, J., Zhu, X., Werbovetz, K., Tidwell, R.R., Clement, J.G., Thornton, S.J., Wasan, K.M., 2010. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral leishmaniasis in a murine model. PLoS Negl. Trop. Dis. 4, e913.
221. Wasan, K.M., 2002. The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Drug Dev. Ind. Pharm. 28, 1047-1058. (Pubitemid 35278830)
222. Williams, H.D., Trevaskis, N.L., Charman, S.A., Shanker, R.M., Charman, W.N., Pouton, C.W., Porter, C.J., 2013. Strategies to address low drug solubility in discovery and development. Pharmacol. Rev. 65, 315-499.
223. Wilschut, J., Papahadjopoulos, D., 1979. Calcium induced fusion of phospholipid vesicles monitored by mixing of aqueous contents. Nature 281, 690-692. (Pubitemid 10249051)
224. Wu, C., Wang, Z., Zhi, Z., Jiang, T., Zhang, J., Wang, S., 2011. Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs. Int. J. Pharm. 403, 162-169.
225. Yanez, J.A., Wang, S.W., Knemeyer, I.W., Wirth, M.A., Alton, K.B., 2011. Intestinal lymphatic transport for drug delivery. Adv. Drug Deliv. Rev. 63, 923-942.
226. Yang, L., Guo, C., Jia, L., Liang, X., Liu, C., Liu, H., 2010. Dual responsive copolymer micelles for drug controlled release. J. Colloid Interf. Sci. 350, 22-29.
227. Yang, Z., Peng, X., Tan, Y., Chen, M., Zhu, X., Feng, M., Xu, Y., Wu, C., 2011. Optimization of the preparation process for an oral phytantriol-based amphotericin B cubosomes. J. Nanomater. 2011, Article ID 308016, 10 pages.
228. Yardley, V., Croft, S.L., De Doncker, S., Dujardin, J.C., Koirala, S., Rijal, S., Miranda, C., Llanos-Cuentas, A., Chappuis, F., 2005. The sensitivity of clinical isolates of leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73, 272-275. (Pubitemid 41278697)
229. Zarif, L., 2005. Drug delivery by lipid cochleates. Methods Enzymol. 391, 314-329. (Pubitemid 40254043)
230. Zarif, L., Graybill, J.R., Perlin, D., Mannino, R.J., 2000a. Cochleates: new lipid-based drug delivery system. J. Liposome Res. 10, 523-538. (Pubitemid 32047474)
231. Zarif, L., Graybill, J.R., Perlin, D., Najvar, L., Bocanegra, R., Mannino, R.J., 2000b. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob. Agents Chemother. 44, 1463-1469. (Pubitemid 30340780)
232. Zarif, L., Jin, T., Segarra, I., Mannino, R.J., 2003. Hydrogel-isolated Cochleate Formulations, Process of Preparation and Their Use for the Delivery of Biologically Relevant Molecules. BioDelivery Sciences International, Inc., University of Medicine and Dentistry of New Jersey, USA.
233. Zhang, Z., Huang, J., Jiang, S., Liu, Z., Gu, W., Yu, H., Li, Y., 2013. Porous starch based self-assembled nano-delivery system improvesthe oral absorption of lipophilic drug. Int. J. Pharm. 444, 162-168.